Phase ii study of thoracic radiation therapy with concurrent cisplatin and etoposide in unresectable non small cell lung cancer

Abstract EN

Purpose : the primary objectives were to determine the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Secondary objectives were evaluation of possible prognostic factors, and toxicity profile.

Methods : induction chemotherapy consisted of Cisplatin S0mg / m2 and etoposide 130 mg / m2 on days 1 through 3 every 28 days for 3 cycles, then concurrent hyper fi'actionated-split course radiation with 1.5 GY per fraction bid up to 60 GY together with 2 cycles of Cisplatin and etoposide in the 1st week and last week, followed by 1-2 cycles of Cisplatin and etoposide given to patients with locally advanced stage III non-small cell lung cancer.

Results: Thirty five patients were enrolled, five were excluded, ORR was 76.7 %, the mean time to tumor progression was 14.57 months, the estimated one year PFS was 73.9 % with CI = 95 %, the two year OS was 21.7 % with CI = 95 %, grade 3 hematological toxicity developed in 6.7 % of patients (n = 2), no more than grade 2 non hematological toxicity was developed.

Conclusion : our protocol was feasible and tolerable, but it did not add any advantage over the standard concurrent chemo radiation.